Kepos Capital LP Fibrogen Inc Transaction History

Kepos Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$23.3 - $45.96 $552,070 - $1.09 Million	-23,694 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$34.58 - $48.06 $340,232 - $472,862	9,839 Added 71.01%	23,694 $1.02 Million
Q3 2019 Nov 13, 2019	BUY	$36.98 - $48.45 $512,357 - $671,274	13,855 New	13,855 $512,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $46.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

Stay updated on Kepos Capital LP with notifications on news.